Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genmab partner Glaxosmithkline to start additional pivotal studies with the subcutaneous formulation of ofatumumab


Friday, 30 May 2014 10:56am EDT 

Genmab A/S:Says its collaboration partner Glaxosmithkline Plc (GSK) has taken the decision to start additional pivotal studies with the subcutaneous formulation of ofatumumab.Phase III studies of subcutaneous ofatumumab in RRMS are expected to begin in 2015, following encouraging data from a Phase II study reported in Oct. 2013.In addition, GSK plans to file an IND for a potential pivotal study of subcutaneous ofatumumab in NMO, a rare autoimmune disorder which affects the optic nerve and spinal cord, during the year. 

Company Quote

47.29
-0.29 -0.61%
17 Apr 2015